Frequency Therapeutics, Inc. (FREQ)
| Market Cap | 359.64M |
| Revenue (ttm) | 36.98M |
| Net Income (ttm) | -26.51M |
| Shares Out | 34.22M |
| EPS (ttm) | -10.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $10.24 |
| Previous Close | $10.51 |
| Change ($) | -0.27 |
| Change (%) | -2.57% |
| Day's Open | 10.52 |
| Day's Range | 9.83 - 10.58 |
| Day's Volume | 584,902 |
| 52-Week Range | 7.34 - 58.37 |
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Their stocks have collapsed. But they could still be huge winners.
A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused ...
These drugmaker stocks may have been hammered down to bargain-bin prices.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ). Such investors are ad...
LOS ANGELES, April 2, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics,...
LOS ANGELES--(BUSINESS WIRE)---- $FREQ #FREQ--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.
New York, New York--(Newsfile Corp. - March 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ). Such i...
LOS ANGELES--(BUSINESS WIRE)---- $FREQ #FREQ--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of 0.00% and -2.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
Frequency Therapeutics Inc. (NASDAQ: FREQ) shares were absolutely crushed in Tuesday's session.
Frequency Therapeutics Inc. (NASDAQ: FREQ) stock imploded Tuesday amid the company's announcement that its interim FX-322 Phase 2a results showed that four weekly injections did not demonstrate improvem...
The company announced disappointing results from a phase 2a study.
Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 i...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly i...
Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors need to pay close attention to Frequency Therapeutics (FREQ) stock based on the movements in the options market lately.
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Frequency Therapeutics Inc (NASDAQ: FREQ) has announced the publication of its lead candidate FX-322 Phase 1/2 study results in Otology & Neurotology. The data was initially announced in April 2019.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
Vir Biotechnology (NASDAQ: VIR) shares are trading lower Wednesday after JPMorgan downgraded the stock from Neutral to Underweight and announced a price target of $30 per share. Vir Biotechnology is a c...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
Frequency Therapeutics (FREQ) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Find Strong Stocks with this New Analyst Coverage Screener
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the body, so ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by ...
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by ...
Frequency Therapeutics Has A Strong Scientific Rationale And An Upcoming Binary Catalyst
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on InvestorPl...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.
Frequency Therapeutics: FX-322 Top Line Data From Exploratory Study Proves Promising
While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.
Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?
Frequency Therapeutics (NASDAQ: FREQ) made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.
About FREQ
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of... [Read more...]
| Industry Biotechnology | IPO Date Oct 3, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol FREQ |
Financial Performance
In 2020, FREQ's revenue was $36.98 million, an increase of 27.76% compared to the previous year's $28.95 million. Losses were -$26.51 million, 41.4% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 124.61% from the latest price.